Bienvenido(a), Visitante. Por favor, ingresa o regístrate.
Febrero 08, 2025, 03:04:10 pm

Ingresar con nombre de usuario, contraseña y duración de la sesión


Usuarios
  • Total de Usuarios: 38039
  • Latest: pthlem
Stats
  • Total de Mensajes: 775866
  • Total de Temas: 66647
  • Online Today: 3419
  • Online Ever: 5484
  • (Junio 18, 2021, 11:15:29 pm)
Usuarios en Línea
Users: 0
Guests: 2413
Total: 2413

Bienvenido


Bienvenido a los Foros Comunitarios de POZ, un área de discusión contínua para personas con VIH/SIDA, sus amigos/familiares/personas que los cuidan, y otros a quienes les interese el tema del VIH/SIDA. Haz clic en los enlaces que siguen para visitar nuestros foros, o participa de la conversación al inscribirte en el sector izquierdo de esta página.

To change forums navigation language settings, click here(Members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí(Sólo miembros), Regístrate ahora

Advertencia sobre la privacidad: Ten en cuenta que estos foros están abiertos para todos y que se los puede encontrar haciendo búsquedas en Google u otros buscadores. Si eres VIH positivo y lo revelas en nuestros foros, es lo mismo que decírselo al mundo entero (o al menos al mundo entero en Internet). Si esto te preocupa, no uses un nombre de usuario o una imagen gráfica que pueda identificarte de alguna manera. No autorizamos borrar nada de los que escribas en los foros, por lo tanto piensa antes de hacerlo.

  • La información que los moderadores y miembros comparten en estos foros, está diseñada para complementar, y no para reemplazar la relación entre un individuo y su médico de cabecera.

  • Todos los miembros de estos foros, en consecuencia, no son considerados proveedores médicos con licencia. De lo contrario, los usuarios deben identificarse a sí mismos como tales.

  • Los miembros de los foros siempre deben comportarse con respeto y honestidad. La publicación de guías, incluyendo políticas de suspensiones y prohibiciones han sido establecidas por los moderadores de estos foros. Haga clic aquí para las guías de publicación de “¿Estoy infectado?” Haga clic aquí para leer las guías de publicación relacionadas con todos los otros foros comunitarios de POZ.

  • Solicitamos a todos los miembros de los foros que proporcionen referencias sobre la información relacionada con la salud/médica/científica que brinden, cuando no se trate de una experiencia personal que estén compartiendo. Por favor proporcionen enlaces con direcciones de Internet completas o citas completas de trabajos publicados que no estén disponibles en Internet. Además, todos los miembros de los foros deben publicar información que sea verdadera y correcta de acuerdo con su conocimiento.

  • Los anuncios de productos – incluyendo enlaces, banderas, contenido editorial y estudios clínicos, estudios o participación en encuestas – está estrictamente prohibido por los miembros de los foros a menos que POZ haya asegurado el permiso.

¿Has terminado de leer esta parte? Puedes cerrar esta o cualquier otra ventana en esta página haciendo click en el símbolo de cada ventana.

Autor Tema: Early Trial of Gilead’s HIV Capsid Inhibitor Supports 3-Month Dosing  (Leído 5639 veces)

0 Usuarios y 1 Visitante están viendo este tema.

Desconectado Jim

  • Administrator
  • Member
  • Mensajes: 23,355
This is an interesting initial trial of this new class of ARV, also its apparently 100x more potent than current ARV's and they are working on an oral formulation.

Poz.com write-up in full: https://www.poz.com/article/early-trial-gileads-hiv-capsid-inhibitor-supports-3month-dosing

In short:

Citar

The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.

Gilead Sciences’ investigational capsid inhibitor GS-6207 showed promise in an early study as a new long-acting form of HIV treatment that could be dosed only every three months. The drug proved safe and well tolerated in a small study including HIV-negative participants.

While GS-6207 was administered via subcutaneous (under the skin) injection in the study, Gilead is attempting to develop an oral formulation of the antiretroviral (ARV).

Capsid inhibitors, a new class of ARV, interfere with the breakdown of the capsid, which shelters HIV’s genetic material, after the virus enters an immune cell. Medications in this class—GS-6207 is the first—also prevent the assembly of the capsid during the production of new viruses after HIV has incorporated its RNA into a cell’s genome.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

Desconectado Loa111

  • Member
  • Mensajes: 385
Re: Early Trial of Gilead’s HIV Capsid Inhibitor Supports 3-Month Dosing
« Respuesta #1 en: Marzo 12, 2019, 09:21:46 am »
So If all went well with this trial & full research process, in years to come, getting this placed under the skin every 3 months could be a treatment option.

Interesting the treatment is 100 times more potent than current ARV's which obviously do a very good job already. I wonder what the benefits of 100 times more potent could be for us?

Desconectado Jim

  • Administrator
  • Member
  • Mensajes: 23,355
Re: Early Trial of Gilead’s HIV Capsid Inhibitor Supports 3-Month Dosing
« Respuesta #2 en: Marzo 12, 2019, 09:40:05 am »
Smaller dosage, anyhow i somehow doubt they will be going down the route of 3 months under the skin initially with this as it still has to be combined with daily pills. (At least that's what I recall reading when I checked)

Maybe more down the line, I would more likely expect this to be tested in pill form combination, than trials of that opening up a new class of ARV. End of the day it hopefully means more combination possibilities and, who knows a new treatment class for people with resistance

We will see, maybe if things go well and fast we might have something in 8-15 years
That's just my thoughts on it of course.
« última modificación: Marzo 12, 2019, 09:58:48 am por JimDublin »
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

Desconectado Mightysure

  • Member
  • Mensajes: 449
Re: Early Trial of Gilead’s HIV Capsid Inhibitor Supports 3-Month Dosing
« Respuesta #3 en: Marzo 12, 2019, 10:25:10 am »
This is great news! I think the potency may mean lower dosing and maybe low resistance profile, like integrase inhibitors.
I think finding a target such as this is very helpful in that there isn't an analogous function of our cells so there is a much lower chance of side effects.

I could see this being combined with other injectables or being attempted as monotherapy for acute infections.


I dont see it as PrEP though.

Desconectado Jim

  • Administrator
  • Member
  • Mensajes: 23,355
Gilead’s HIV Capsid Inhibitor Worked Well in 1st Human Trial
« Respuesta #4 en: Julio 24, 2019, 05:35:05 am »
A follow-up to the above posting on Gilead’s HIV Capsid Inhibitor

Full write-up
https://www.poz.com/article/gileads-hiv-capsid-inhibitor-worked-1st-human-trial

In Short:
Gilead’s HIV Capsid Inhibitor Worked Well in 1st Human Trial

Citar
Findings from the two studies of GS-6207 were presented in a pair of posters at the 10th International AIDS Society Conference on HIV Science in Mexico City (IAS 2019).

In an ongoing Phase Ib trial, 24 people with HIV who had not previously been treated with a capsid inhibitor received one subcutaneous injection of GS-6207. They were randomized into three even groups of six people each to receive a 50 milligram, 150 mg or 450 mg dose of the drug or a placebo.

Ten days after their injection, those who received GS-6207 experienced an average maximum reduction in viral load of 98.4% to 99.3% (1.8 to 2.2 log10). All these reductions were significantly greater than that seen among those who received the placebo.

None of the participants experienced a serious adverse health event or dropped out of the study because of adverse health events. The most common adverse events were mild to moderate reactions at the point of injection, experienced by 63% (15 of 24) of the participants.

In a separate laboratory study, researchers studied the emergence of resistance to GS-6207 in HIV-infected cells when the drug was administered at levels below the threshold considered appropriate for treating the virus. In this context, the drug prompted HIV to develop mutations related to the viral capsid known as L56I, M661, Q67H, K70N, N74D/S and T107N.

Virus that had at least one of these mutations had a diminished response to GS-6207 but had no such reduction in its susceptibility to other classes of ARVs. Such drug resistance was commonly associated with a compromised ability of HIV to infect cells as well as an impaired capacity to replicate within cells.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

 


Terms of Membership for these forums
 

© 2025 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.